Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.57 |
| ▸ | PLK1 | P53350 | 4/20 | 0.52 |
| ▸ | THRA | P10827 | 6/20 | 0.50 |
| ▸ | THRB | P10828 | 6/20 | 0.50 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1878644 | 1.00 | ASAH2 (0.57) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL1878645 | 1.00 | ASAH2 (0.57) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL1880385 | 1.00 | ASAH2 (0.57) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL1880381 | 1.00 | ASAH2 (0.57) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL1875630 | 1.00 | ASAH2 (0.57) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL1880076 | 0.85 | SPHK2 (0.52) | ASAH2SPHK2SPHK1 | |
| SCHEMBL1880075 | 0.85 | SPHK2 (0.52) | ASAH2SPHK2SPHK1 | |
| SCHEMBL12672300 | 0.84 | ASAH2 (0.63) | ASAH2PLK1THRATHRBRARB | |
| SCHEMBL11972669 | 0.82 | PPARG (0.66) | PLK1RARBSPHK1 | |
| SCHEMBL4220014 | 0.81 | ASAH2 (0.59) | ASAH2PLK1THRATHRBRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110106241-A1 | COMPOSITIONS AND METHODS FOR INHIBITING SPHINGOSINE KINASE | SPHK2, SPHK1, S1PR2 | ASAH2 68/4885PLK1 228/4885THRA 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.